<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0206547</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-14252</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic endocrinology</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Epithelial cells</subject><subj-group><subject>Endothelial cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological tissue</subject><subj-group><subject>Epithelium</subject><subj-group><subject>Epithelial cells</subject><subj-group><subject>Endothelial cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological tissue</subject><subj-group><subject>Epithelium</subject><subj-group><subject>Epithelial cells</subject><subj-group><subject>Endothelial cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive science</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject><subj-group><subject>Type 2 diabetes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject><subj-group><subject>Type 2 diabetes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer’s disease and normalized by treatment with anti-diabetic agents</article-title>
<alt-title alt-title-type="running-head">Endothelial and insulin receptor signaling pathways in Alzheimer’s disease and type 2 diabetes</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Katsel</surname>
<given-names>P.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4640-6239</contrib-id>
<name name-style="western">
<surname>Roussos</surname>
<given-names>P.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Software</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Beeri</surname>
<given-names>M. S.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Gama-Sosa</surname>
<given-names>M. A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Gandy</surname>
<given-names>S.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Khan</surname>
<given-names>S.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5860-2512</contrib-id>
<name name-style="western">
<surname>Haroutunian</surname>
<given-names>V.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Mental Illness Research, Education and Clinical Center, J.J. Peters VA Medical Center, Bronx, New York, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Aviv, Israel</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Division of Neurology, J.J. Peters VA Medical Center, Bronx, New York, United States of America</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>General Medical Research Service, J.J. Peters VA Medical Center, Bronx, New York, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Ginsberg</surname>
<given-names>Stephen D</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Nathan S Kline Institute, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">vahram.haroutunian@mssm.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>1</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>11</issue>
<elocation-id>e0206547</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">
<license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">Creative Commons CC0</ext-link> public domain dedication.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0206547"/>
<abstract>
<p>A large body of literature links risk of cognitive decline, mild cognitive impairment (MCI) and dementia with Type 2 Diabetes (T2D) or pre-diabetes. Accumulating evidence implicates a close relationship between the brain insulin receptor signaling pathway (IRSP) and the accumulation of amyloid beta and hyperphosphorylated and conformationally abnormal tau. We showed previously that the neuropathological features of Alzheimer’s disease (AD were reduced in patients with diabetes who were treated with insulin and oral antidiabetic medications. To understand better the neurobiological substrates of T2D and T2D medications in AD, we examined IRSP and endothelial cell markers in the parahippocampal gyrus of controls (N = 30), of persons with AD (N = 19), and of persons with AD and T2D, who, in turn, had been treated with anti-diabetic drugs (insulin and or oral agents; N = 34). We studied the gene expression of selected members of the IRSP and selective endothelial cell markers in bulk postmortem tissue from the parahippocampal gyrus and in endothelial cell enriched isolates from the same brain region. The results indicated that there are considerable abnormalities and reductions in gene expression (bulk tissue homogenates and endothelial cell isolates) in the parahippocampal gyri of persons with AD that map directly to genes associated with the microvasculature and the IRSP. Our results also showed that the numbers of abnormally expressed microvasculature and IRSP associated genes in diabetic AD donors who had been treated with anti-diabetic agents were reduced significantly. These findings suggest that anti-diabetic treatments may reduce or normalize compromised microvascular and IRSP functions in AD.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000738</institution-id>
<institution>U.S. Department of Veterans Affairs</institution>
</institution-wrap>
</funding-source>
<award-id>1 I21 RX002069-01</award-id>
<principal-award-recipient>Miguel A Gama-Sosa</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000738</institution-id>
<institution>U.S. Department of Veterans Affairs</institution>
</institution-wrap>
</funding-source>
<award-id>1 I21 RX002876-01</award-id>
<principal-award-recipient>Miguel A Gama-Sosa</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000738</institution-id>
<institution>U.S. Department of Veterans Affairs</institution>
</institution-wrap>
</funding-source>
<award-id>BX002267</award-id>
<principal-award-recipient>Vahram Haroutunian</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>N01HHSN 271201300031</award-id>
<principal-award-recipient>Vahram Haroutunian</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>P50 AG005138-31</award-id>
<principal-award-recipient>Vahram Haroutunian</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>AG034087</award-id>
<principal-award-recipient>Michal S Beeri</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>AG053446</award-id>
<principal-award-recipient>Michal S Beeri</principal-award-recipient>
</award-group>
<award-group id="award008">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>AG051545</award-id>
<principal-award-recipient>Michal S Beeri</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1 I21 RX002069-01 and 1 I21 RX002876-01 (MAGS); VA Merit BX002267, NIH- N01HHSN 271201300031, P50 AG005138-31 (VH); R01 AG034087, R01 AG053446, R01 AG051545 (MSB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>A significant body of literature links risk of cognitive decline, mild cognitive impairment (MCI), and dementia with Type 2 Diabetes (T2D) or pre-diabetes[<xref ref-type="bibr" rid="pone.0206547.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0206547.ref002">2</xref>]. T2D or impaired fasting glucose may be present in up to 80% of persons with Alzheimer’s disease (AD)[<xref ref-type="bibr" rid="pone.0206547.ref003">3</xref>]. Modifications in brain insulin metabolism are thought to be among the pathophysiological factors underlying dementia, whether due to AD[<xref ref-type="bibr" rid="pone.0206547.ref004">4</xref>] or to vascular cognitive impairment and dementia (VCID). Several studies suggest that pre-diabetes[<xref ref-type="bibr" rid="pone.0206547.ref005">5</xref>] and T2D may anticipate conversion to MCI[<xref ref-type="bibr" rid="pone.0206547.ref002">2</xref>, <xref ref-type="bibr" rid="pone.0206547.ref006">6</xref>]. Imaging studies suggest significant changes in the brain microvasculature and in metabolic dysfunction[<xref ref-type="bibr" rid="pone.0206547.ref007">7</xref>] in persons with T2D, or even simple hyperglycemia in the absence of full blown diabetes, and dementia[<xref ref-type="bibr" rid="pone.0206547.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0206547.ref010">10</xref>]. Accumulating evidence implicates a close relationship between the brain insulin receptor signaling pathway (IRSP) and the major neurobiological abnormalities of AD, amyloid beta (Aβ) and hyperphosphorylated and conformationally abnormal tau. Both pathologies have been shown to lower neuronal IR responses to insulin and to cause rapid and substantial loss of neuronal surface insulin receptors (IRs)[<xref ref-type="bibr" rid="pone.0206547.ref011">11</xref>]. Disruption of brain insulin signaling is one of the explanations for the consistently higher risk of AD and dementia in type 2 diabetic elderly[<xref ref-type="bibr" rid="pone.0206547.ref012">12</xref>]. Fat-feed laboratory transgenic mice models of AD that overexpress brain amyloidogenic genes develop glucose intolerance and insulin resistance, illustrating the potential bidirectional complexity of this relationship[<xref ref-type="bibr" rid="pone.0206547.ref013">13</xref>]. In AD patients, monotherapy with insulin[<xref ref-type="bibr" rid="pone.0206547.ref014">14</xref>] or with single representatives of other classes of hypoglycemic medications[<xref ref-type="bibr" rid="pone.0206547.ref015">15</xref>, <xref ref-type="bibr" rid="pone.0206547.ref016">16</xref>] have been shown to not alter the risk of AD[<xref ref-type="bibr" rid="pone.0206547.ref017">17</xref>], but to potentially improve memory performance and slow cognitive decline. That cognitive impairment and AD neuropathology have been linked with T2D and even pre-diabetes suggests that the mechanisms underlying the relationship of T2D with dementia may be generalizable to non-T2D individuals. Although not performed on brain tissue, a recent study strongly supports an association between the molecular mechanisms of AD, insulin regulation, and T2D[<xref ref-type="bibr" rid="pone.0206547.ref018">18</xref>]. Integrative systems analysis of multiple tissues and organs in <italic>ob/ob</italic> mice identified APP as a top regulator of islet cell functions with the potential to regulate plasma insulin levels. This and other evidence for the complexity of the T2D-dementia interaction was comprehensively reviewed by Arnold and colleagues[<xref ref-type="bibr" rid="pone.0206547.ref019">19</xref>].</p>
<p>Recent evidence[<xref ref-type="bibr" rid="pone.0206547.ref020">20</xref>] suggests that metformin, and by extension other hypoglycemic medications[<xref ref-type="bibr" rid="pone.0206547.ref021">21</xref>], can significantly improve health- and lifespan. For example, metformin has the unique ability to correct the aging-related missorting of nuclear and cytoplasmic proteins[<xref ref-type="bibr" rid="pone.0206547.ref022">22</xref>]. In non-diabetic AD patients, monotherapy with insulin[<xref ref-type="bibr" rid="pone.0206547.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0206547.ref024">24</xref>] or with other hypoglycemic medications[<xref ref-type="bibr" rid="pone.0206547.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0206547.ref025">25</xref>] has shown some, albeit inconsistent, improvement in memory performance and slowing of AD symptom progression. In a series of studies[<xref ref-type="bibr" rid="pone.0206547.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0206547.ref027">27</xref>], our group showed that, when taken as a whole, T2D did not significantly affect the neuropathological sequelae of AD, but that the absence of a “T2D X AD neuropathology” interaction was apparently driven in large measure by the presence of antidiabetic drugs. Our studies showed that elderly persons with T2D treated with insulin <underline><italic>plus</italic></underline> other hypoglycemic agents (i.e., combination therapy) have dramatically less AD neuropathology (reduced densities of neuritic plaques and neurofibrillary tangles in the cortex) than otherwise similar non-T2D persons<sup>2</sup>. In an effort to understand better the neurobiological substrates of T2D and T2D medications in AD, we examined in the current study IRSP and endothelial cell markers in the parahippocampal gyri of persons with and without AD, T2D and T2D medications.</p>
<p>Insulin receptors (IR) are particularly abundant in brain regions supporting cognition, with recent evidence implicating a close relationship between the brain IR signaling pathway (IRSP) and the major neurobiological abnormalities of accumulations of Aβ and of conformationally abnormal and hyperphosphorylated tau (pTau)<sup>e.g.,</sup>[<xref ref-type="bibr" rid="pone.0206547.ref028">28</xref>]. <italic>In vitro</italic> studies<sup>3-5</sup> provide support for our findings identifying the IRSP as an underlying mechanism by which combination of insulin with non-insulin T2D medications may modulate AD neuropathology even in the absence of comorbid T2D. Insulin binds to IR subunits (member of the receptor tyrosine kinase family engaging Akt and mTOR pathways). Phosphorylated insulin receptor substrate (IRS) scaffolding proteins link the IR to downstream signaling effectors including Akt. Akt activation inhibits pro-apoptotic signaling molecules such as BCL2-antagonist of cell death (BAD), B cell lymphoma 2 (BCL2), Forkhead Box O (FoxO), nuclear factor kappa B (NF-κB) and glycogen synthase kinase-3 beta (GSK3β). GSK3β by itself inhibits Akt by controlling mTORC, a key activating kinase for AKT[<xref ref-type="bibr" rid="pone.0206547.ref029">29</xref>]. GSK3β also phosphorylates β-catenin, targeting it for ubiquitination and proteasome dependent degradation[<xref ref-type="bibr" rid="pone.0206547.ref030">30</xref>]. Independent evidence implicates elements of this pathway in neuronal dysfunction, neurodegeneration and dementia[<xref ref-type="bibr" rid="pone.0206547.ref031">31</xref>–<xref ref-type="bibr" rid="pone.0206547.ref034">34</xref>]. In addition to this canonical “metabolic and anti-apoptotic” pathway of the IRSP, insulin binding to IR can also activate a second, SHC-ERK1/2, pro-survival pathway culminating in the activation of PPAR, and its coactivator PGC-1α, and interactions with the master cholesterol regulators RxR and LxR[<xref ref-type="bibr" rid="pone.0206547.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0206547.ref036">36</xref>]. Notably, these are the molecules that our studies indicate to be dysregulated in postmortem human AD brain[<xref ref-type="bibr" rid="pone.0206547.ref037">37</xref>, <xref ref-type="bibr" rid="pone.0206547.ref038">38</xref>]. The IRSP in the brain contributes to the control of processes such as synaptic plasticity, e.g.,[<xref ref-type="bibr" rid="pone.0206547.ref027">27</xref>] [<xref ref-type="bibr" rid="pone.0206547.ref033">33</xref>, <xref ref-type="bibr" rid="pone.0206547.ref034">34</xref>], neuroprotection, neurodegeneration, survival, growth, and energy metabolism, e.g.,[<xref ref-type="bibr" rid="pone.0206547.ref039">39</xref>], all of which are particularly relevant to cognition.</p>
<p>The mechanism by which insulin is delivered to the brain is uncertain, but insulin receptors (IR) on endothelial cells are the leading candidates[<xref ref-type="bibr" rid="pone.0206547.ref040">40</xref>]. Several non-mutually exclusive mechanisms may underlie the association between T2D and dementia, but increased cerebrovascular compromise and blood-brain barrier disruption[<xref ref-type="bibr" rid="pone.0206547.ref041">41</xref>–<xref ref-type="bibr" rid="pone.0206547.ref043">43</xref>]; defective signal transduction mechanism of central nervous system insulin receptors[<xref ref-type="bibr" rid="pone.0206547.ref044">44</xref>, <xref ref-type="bibr" rid="pone.0206547.ref045">45</xref>]; and their potential interactions with amyloidogenic processes[<xref ref-type="bibr" rid="pone.0206547.ref044">44</xref>, <xref ref-type="bibr" rid="pone.0206547.ref046">46</xref>–<xref ref-type="bibr" rid="pone.0206547.ref048">48</xref>] are among the most prominent <sup>see also</sup>, [<xref ref-type="bibr" rid="pone.0206547.ref019">19</xref>]. Multiple studies have suggested that microvascular dysfunction, including permeability of the blood-brain barrier[<xref ref-type="bibr" rid="pone.0206547.ref049">49</xref>–<xref ref-type="bibr" rid="pone.0206547.ref052">52</xref>], may be a significant contributor to cognitive impairment in the elderly and in VCID or AD[<xref ref-type="bibr" rid="pone.0206547.ref053">53</xref>]. This evidence has come not only from numerous neuroimaging studies of microvascular dysfunction[<xref ref-type="bibr" rid="pone.0206547.ref054">54</xref>–<xref ref-type="bibr" rid="pone.0206547.ref056">56</xref>], but also from direct neuropathological investigations[<xref ref-type="bibr" rid="pone.0206547.ref057">57</xref>–<xref ref-type="bibr" rid="pone.0206547.ref065">65</xref>] and animal model systems[<xref ref-type="bibr" rid="pone.0206547.ref066">66</xref>, <xref ref-type="bibr" rid="pone.0206547.ref067">67</xref>]. Similarly, microvascular damage and involvement, including dysfunction of endothelial cells in T2D, is undeniable[<xref ref-type="bibr" rid="pone.0206547.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0206547.ref055">55</xref>, <xref ref-type="bibr" rid="pone.0206547.ref056">56</xref>, <xref ref-type="bibr" rid="pone.0206547.ref068">68</xref>–<xref ref-type="bibr" rid="pone.0206547.ref071">71</xref>]. On the other hand, IRs in the brain do not appear to downregulate dramatically in response to high concentrations of insulin, and—in contrast to its role in glia and peripheral cells—insulin has a relatively limited role in regulating glucose metabolism in neurons[<xref ref-type="bibr" rid="pone.0206547.ref020">20</xref>, <xref ref-type="bibr" rid="pone.0206547.ref072">72</xref>] and densities of IRs are not adversely affected in AD[<xref ref-type="bibr" rid="pone.0206547.ref047">47</xref>] when studied in bulk tissue assays. However, the vast majority of the studies of the brain IRSP in AD and T2D have been conducted in homogenized bulk tissue where even large changes and abnormalities in one or more cell types can be diluted or completely obscured when different cell types are intermixed in bulk-homogenate studies. In order to overcome this limitation and to address more directly the roles of T2D and antidiabetic medication in AD, we developed a method of endothelial cell enrichment from bulk human postmortem brain tissue and studied components of the IRSP and markers of endothelial cell function.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Tissue processing</title>
<p>This study involved analysis of postmortem human brain samples only. Consent for research use of the tissue was obtained from all donors. The collection and consent procedures were reviewed by the Mount Sinai (HS#: 13–00709 PS) and JJ Peters VA (ID01527) IRBs and were exempted from further review. The parahippocampal gyrus (Brodmann 36), was dissected from snap-frozen ~8 mm thick coronal sections. The dissected block was then pulverized using liquid nitrogen cooled mortar and pestle. The crushed homogenate was aliquoted into 50 and 100 mg aliquots. The general procedures for tissue acquisition, dissection and aliquot preparation have been described previously[<xref ref-type="bibr" rid="pone.0206547.ref073">73</xref>]. Some aliquots were used for bulk tissue analyses, whereas other sister aliquots from the same brain region of each donor were used for endothelial cell enrichment.</p>
</sec>
<sec id="sec004">
<title>Gene expression studies</title>
<p>Custom 51-plex QuantiGene assays (Life Technologies/Thermo, CA) were used for gene expression studies. Tissue and microvessel isolate homogenization, proteinase K treatment, probe hybridization and signal amplification were performed according to the manufacturer manual. Measurement of 51 genes (<xref ref-type="table" rid="pone.0206547.t001">Table 1</xref>, and <xref ref-type="supplementary-material" rid="pone.0206547.s001">S1 File</xref>) was performed on Luminex 200 (Millipore, MA) instrument. Relative expression values were calculated using standard curve method and normalized to geometric means of four housekeeping genes included in the panel: <italic>HMBS</italic>, <italic>NONO</italic>, <italic>PPIB and RPLP0</italic>.</p>
<table-wrap id="pone.0206547.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of the primary study cohorts.</title></caption>
<alternatives>
<graphic id="pone.0206547.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left"/>
<td align="left">Mean PMI (Hours)</td>
<td align="left">Mean CDR</td>
<td align="left">Mean Age</td>
<td align="left">Sex</td>
<td align="left">Mean Cortical Plaques per mm^2</td>
<td align="left">Mean Braak &amp; Braak Score</td>
<td align="left">Race (white; Black; Hispanic</td>
<td align="left">Mean Blood glucose (mg/dl)</td>
</tr>
<tr>
<td align="left">Control (N = 30)</td>
<td align="left">12.85 (1.4)</td>
<td align="left">0.43 (0.13)</td>
<td align="left">83.17 (1.48)</td>
<td align="left">14F; 16M</td>
<td align="left">0.83 (0.32)</td>
<td align="left">1.5 (0.32)</td>
<td align="left">26; 3; 1</td>
<td align="left">95.5 (22)</td>
</tr>
<tr>
<td align="left">AD (N = 19)<xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="left">6.88 (1.17)</td>
<td align="left">3.0 (0.28)</td>
<td align="left">88.26 (2.01)</td>
<td align="left">15F; 4M</td>
<td align="left">9.58 (1.38)</td>
<td align="left">4.89 (0.29)</td>
<td align="left">17; 2; 1</td>
<td align="left">119.4 (8)</td>
</tr>
<tr>
<td align="left">AD+DM+Meds (N = 34)<xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="left">7.67 (0.98)</td>
<td align="left">2.89 (0.26)</td>
<td align="left">84.61 (1.49)</td>
<td align="left">23F; 11M</td>
<td align="left">8.39 (0.86)</td>
<td align="left">4.64 (0.26)</td>
<td align="left">26; 5; 3</td>
<td align="left">148.8 (14)</td>
</tr>
<tr>
<td align="left" colspan="9">Medication Characteristics of the AD+DM+Meds (N = 34 cohort)</td>
</tr>
<tr>
<td align="left" colspan="3">Medication Subset</td>
<td align="left" colspan="3">Percent of Subset</td>
<td align="left" colspan="3">Medication class</td>
</tr>
<tr>
<td align="left" colspan="3">Insulin Only</td>
<td align="left" colspan="3">N = 15 (45%)</td>
<td align="left" colspan="3">Insulin</td>
</tr>
<tr>
<td align="left" colspan="3">Oral Only</td>
<td align="left" colspan="3">N = 12 (35%)</td>
<td align="left" colspan="3">N = 9 (75%) Sulfonylurea<break/>N = 2 (17%) Metformin<break/>N = 1 (8%) Thiazolidinedione</td>
</tr>
<tr>
<td align="left" colspan="3">Insulin + Oral</td>
<td align="left" colspan="3">N = 7 (21%)</td>
<td align="left" colspan="3">N = 5 (79%) Sulfonylurea<break/>N = 2 (21%) Metformin</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>* 17% (N = 9) of cases with AD (with or without DM medications) were treated with medications for AD (one was treated with memantine and 8 received donepezil) which were terminated at least 14 months prior to death.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec005">
<title>Selection of mRNA transcripts for expression studies</title>
<p>Twenty-four to twenty-six mRNA transcripts were selected for study. The selection of transcripts was based on several factors that included: known association with the IRSP; known and relatively enriched expression in endothelial cells[<xref ref-type="bibr" rid="pone.0206547.ref074">74</xref>], and relatively high or altered expression in bulk tissue microarray studies of AD[<xref ref-type="bibr" rid="pone.0206547.ref075">75</xref>, <xref ref-type="bibr" rid="pone.0206547.ref076">76</xref>]. Twenty-three other transcripts associated with immune-inflammation, neurons, oligodendrocytes, astrocytes and microglia were also studied to survey other systems that may have been affected by T2D medications. The results of these later assays are shown in <xref ref-type="supplementary-material" rid="pone.0206547.s001">S1 File</xref>.</p>
</sec>
<sec id="sec006">
<title>Microvascular/endothelial cell enrichment</title>
<p>One hundred milligrams of brain tissue was gently homogenized in cold 18% dextran/PBS containing protectRNA RNase inhibitor (Sigma, MO) (10 ml/g of tissue) using a Potter-Elvejehm with a loose-fit Teflon pestle (6–8 strokes at low speed)[<xref ref-type="bibr" rid="pone.0206547.ref077">77</xref>]. The homogenate was overlaid onto an equal volume of a discontinuous gradient of Ficoll-Paque PLUS<sup>™</sup> and centrifuged for 30 min at 1,500 x g and 4°C. The resulting microvascular enriched pellet was resuspended and washed twice with PBS. The isolated microvascular/endothelial cell fragment was frozen and stored at -80C until further assays. In preliminary multiple gene expression studies, we have found this protocol to results in a significant (3–7 fold depending on the endothelial cell marker used) enrichment of microvascular/endothelial cell markers and a many-fold reduction in the levels of non-endothelial cell markers. <xref ref-type="fig" rid="pone.0206547.g001">Fig 1</xref> shows one such example.</p>
<fig id="pone.0206547.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Enrichment of endothelial cell transcripts in microvascular isolates.</title>
<p>The expression levels of selected endothelial cell markers and non-endothelial markers are expressed as fold change ratios relative to the levels of each transcript in bulk tissue homogenates.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec007">
<title>Characteristics of brain tissue donors and molecular pathways of interest</title>
<p>The demographic characteristics and group stratification of study cases is shown in <xref ref-type="table" rid="pone.0206547.t001">Table 1</xref>. All postmortem brain tissue donors were derived from the Mount Sinai NIH Neurobiobank (<ext-link ext-link-type="uri" xlink:href="http://icahn.mssm.edu/research/nih-brain-tissue-repository/about" xlink:type="simple">http://icahn.mssm.edu/research/nih-brain-tissue-repository/about</ext-link>). All brain tissue donations were derived from cases with written consent from the next of kin of each donor for research use. Each brain underwent a detailed neuropathological assessment as described previously[<xref ref-type="bibr" rid="pone.0206547.ref078">78</xref>, <xref ref-type="bibr" rid="pone.0206547.ref079">79</xref>]. Donors were selected from over 1,900 cases for short postmortem interval (under 24 hours), high brain tissue pH (&gt;6.0), the presence of either only AD pathology (as defined by CERAD[<xref ref-type="bibr" rid="pone.0206547.ref080">80</xref>]) or no evidence of neuropathology. Brodmann area 36 (the parahippocampal gyrus) was selected for study because transcriptome-wide analysis of 17 different brain regions showed it to be among the most transcriptionally vulnerable brain region in AD[<xref ref-type="bibr" rid="pone.0206547.ref076">76</xref>]. To enable direct comparison of assayed IRSP and endothelial cell mRNA expression, cases with AD and no known history of T2D were selected to match those with AD and a history of T2D as closely as possible with respect to both pre-agonal cognitive function and severity of neuropathology as defined by Braak score and density of cortical neuritic plaques. Cases with neuropathological evidence of non-AD pathology (e.g., Lewy body pathology, significant vascular pathology such as stroke or amyloid angiopathy, etc.) were excluded from all studies as described previously. Donors were included as presenting with T2D based on the American Diabetes Association criteria (symptoms of diabetes plus casual plasma glucose concentration &gt; 200mg/dl; fasting plasma glucose &gt; 126mg/dl; 2h plasma glucose&gt;200mg/dl during OGTT); and/or record of receiving anti-diabetes medication; history of diabetes in the medical record. Diagnoses of T2D were ascertained from detailed structured review (&gt;275 items) of all medical records and medical history. Similarly, medication use history and laboratory test results were derived from detailed reviews of medical records and semi-structured guided interviews of the next of kin or caregivers intimately acquainted with the donor.</p>
</sec>
<sec id="sec008">
<title>Statistical methods</title>
<p>Differential expression between disease status (control, AD) and treatment (insulin and/or oral anti-diabetes agents) was assessed using the limma package in R, with normalized gene expression matrix and the final covariate model, which included gender and PMI. Note that the analysis was run separately for gene expression derived from vessels and homogenate tissue. For each gene, least-squares linear regression was performed using limma to yield coefficients for the effect on gene expression of each variable on the right-hand side:
<disp-formula id="pone.0206547.e001">
<alternatives>
<graphic id="pone.0206547.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pone.0206547.e001" xlink:type="simple"/>
<mml:math display="block" id="M1">
<mml:mrow><mml:mtext>gene</mml:mtext><mml:mspace width="4pt"/><mml:mtext>expression</mml:mtext><mml:mo>∼</mml:mo><mml:mtext>Group</mml:mtext><mml:mo>+</mml:mo><mml:mtext>Gender</mml:mtext><mml:mo>+</mml:mo><mml:mtext>PMI</mml:mtext><mml:mo>;</mml:mo></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
where Group is defined based on combination of diagnosis and treatment [i.e., control, AD (no T2D, no T2D medications), and AD+T2D treated with insulin and/or oral anti-diabetes agents]. <italic>P</italic> values were adjusted for multiple hypothesis testing using false discovery rate (FDR) estimation, and the differentially expressed genes were determined as those with an estimated FDR ≤ 5%, or where specified FDR ≤ 7%.</p>
</sec>
</sec>
<sec id="sec009" sec-type="results">
<title>Results</title>
<p>The main analyses were performed on the expression of the genes shown in <xref ref-type="table" rid="pone.0206547.t002">Table 2</xref> with the primary goal of determining the extent to which IRSP and endothelial cell related transcripts were altered in AD vs. controls and whether these disease-associated changes were normalized in the brain of persons with AD receiving one or more antidiabetic medications of any kind and in any combination (i.e., insulin only, oral agents only, insulin plus oral agents).</p>
<table-wrap id="pone.0206547.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.t002</object-id>
<label>Table 2</label> <caption><title>Abbreviations, brief function and cell-type expression and expression levels of IRSP and endothelial cell transcripts in AD-tissue and vessels.</title></caption>
<alternatives>
<graphic id="pone.0206547.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Symbol</th>
<th align="left">Description</th>
<th align="left">System</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>ANGPT1</italic></td>
<td align="left"><bold>Angiopoietin 1</bold> is involved in vascular development and angiogenesis.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=ANGPT1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=ANGPT1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>CD59</italic></td>
<td align="left"><bold>CD59 glycoprotein</bold>, aka <bold>MAC-inhibitory protein</bold> is mostly expressed in endothelial cells and oligodendrocytes.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=CD59" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=CD59</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>CTNNB1</italic></td>
<td align="left"><bold>Catenin beta-1</bold>, AKA <bold>β-catenin</bold>, is involved in regulation and coordination of cell–cell adhesion and gene transcription. It is a member of the Wnt signaling pathway. Highest expression is in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=CTNNB1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=CTNNB1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>FLT1</italic></td>
<td align="left"><bold>Vascular endothelial growth factor receptor 1</bold> shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. It is exclusively expressed in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=flt1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=flt1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>FOXF2</italic></td>
<td align="left"><bold>Forkhead box protein F2</bold>. FOXF2 functions are not understood well, but it is expressed almost exclusively in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=FOXF2" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=FOXF2</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>ICAM1</italic></td>
<td align="left"><bold>Intercellular Adhesion Molecule 1</bold> aka <bold>D54</bold> (<bold>C</bold>luster of <bold>D</bold>ifferentiation 54) encodes a cell surface glycoprotein which is expressed on endothelial cells and cells of the immune system.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=ICAM1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=ICAM1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>IGF1R</italic></td>
<td align="left"><bold>Insulin-like growth factor 1 (IGF-1) receptor</bold> belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF-1 is highly expressed in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=IGF1R" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=IGF1R</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>PDGFRB</italic></td>
<td align="left"><bold>Beta-type platelet-derived growth factor receptor</bold> Activation of PDGFRβ requires de-repression of the receptor’s kinase activity which is accomplished during PDGFRβ dimerization. Two of the five PDGF isoforms activate PDGFRβ (PDGF-B and PDGF-D) which phosphorylates itself and other proteins, and engages intracellular signaling pathways associated with migration and proliferation. PDGFRβ is mostly expressed in astrocytes and endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PDGFRB" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PDGFRB</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>PECAM1</italic></td>
<td align="left"><bold>Platelet endothelial cell adhesion molecule</bold> aka CD31, plays a key role in removing aged neutrophils from the body. PECAM-1 is found on the surface of platelets, monocytes, neutrophils, and some types of T-cells, and makes up a large portion of endothelial cell intercellular junctions. The encoded protein is a member of the immunoglobulin superfamily, it is expressed almost exclusively on endothelial cells and is likely involved in leukocyte transmigration, angiogenesis, and integrin activation.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PECAM1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PECAM1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>SLC2A1</italic></td>
<td align="left"><bold>Glucose transporter 1</bold> (or <bold>GLUT1</bold>), aka <bold>solute carrier family 2, facilitated glucose transporter member 1</bold> is expressed mainly in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=SLC2A1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=SLC2A1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>VCAM1</italic></td>
<td align="left"><bold>Vascular cell adhesion protein 1</bold> is expressed on both large and small blood vessels only after the endothelial cells are stimulated by cytokines. The VCAM-1 protein mediates the adhesion of lymphocytes, monocytes, eosinophils, and basophils to the vascular endothelium. Upregulation of VCAM-1 in endothelial cells by cytokines occurs as a result of increased gene transcription (e.g., in response to Tumor necrosis factor-alpha (TNF-α) and Interleukin-1 (IL-1)). VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of integrins. It is almost exclusively expressed in astroglial.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VCAM1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VCAM1</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>VEGFA</italic></td>
<td align="left"><bold>Vascular endothelial growth factor A</bold> is a member of the platelet-derived growth factor (PDGF) family. It acts on endothelial cells to increase permeability. It is expressed in mostly in astrocytes but also in neurons and OPCs.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VEGFA" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VEGFA</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="left"><italic>VWF</italic></td>
<td align="left"><bold>Von Willebrand factor</bold> is expressed mostly in endothelial cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VWF" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=VWF</ext-link></td>
<td align="center">Endothelial related</td>
</tr>
<tr>
<td align="center" colspan="3" style="background-color:#b3b3b3"/>
</tr>
<tr>
<td align="left"><italic>AKT1</italic></td>
<td align="left"><bold>V-akt murine thymoma viral oncogene homolog 1; AKT1</bold> gene encodes an <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Enzyme" xlink:type="simple">enzyme</ext-link> in the serine/threonine kinase family and is a key signaling molecule in the IRSP.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=AKT1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=AKT1</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>AKT3</italic></td>
<td align="left"><bold>v-akt murine thymoma viral oncogene homolog 3; AKT3</bold>, regulates cell signaling in response to insulin and growth factors.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=AKT3" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=AKT3</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>DDIT4</italic></td>
<td align="left"><bold>DNA-damage-inducible transcript 4 protein</bold> (<bold>DDIT4</bold>) acts as a negative regulator of mTOR. Metformin increases DDIT4 expression.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=DDIT4" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=DDIT4</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>FTO</italic></td>
<td align="left"><bold>Fat mass and obesity-associated protein</bold>.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=FTO" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=FTO</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>GSK3B</italic></td>
<td align="left"><bold>Glycogen synthase kinase 3 beta</bold>, is a kinase and part of the IRSP.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=GSK3B" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=GSK3B</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>INSR</italic></td>
<td align="left"><bold>Insulin receptor</bold> (<bold>IR</bold>) is an insulin, IGF-I and IGF-II activated transmembrane receptor that is expressed in most cells.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=INSR" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=INSR</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>IRS1</italic></td>
<td align="left"><bold>Insulin receptor substrate</bold> participates in transmitting signals from the insulin and insulin-like growth factor-1 (IGF-1) receptors to intracellular pathways PI3K / Akt and Erk MAP kinase pathways.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=IRS1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=IRS1</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>IRS2</italic></td>
<td align="left"><bold>Insulin receptor substrate 2</bold> is a cytoplasmic signaling molecule that mediates effects of insulin, insulin-like growth factor 1, and some cytokines by acting as a molecular adaptor between diverse receptor tyrosine kinases.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=irs2" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=irs2</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>MTOR</italic></td>
<td align="left"><bold>mechanistic target of</bold> <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Sirolimus" xlink:type="simple">rapamycin</ext-link> (<bold>mTOR</bold>), (formerly <bold>mammalian target of rapamycin</bold>) is a serine/threonine kinase and is part of the IRSP.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=MTOR" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=MTOR</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>PPARGC1A</italic></td>
<td align="left"><bold>Peroxisome proliferator-activated receptor gamma coactivator 1-alpha</bold> regulates genes associated with energy metabolism. PPARGC1A interacts with the nuclear receptor PPAR-γ and is a downstream member of the IRSP. It is expressed in astrocytes, neurons and oligodendrocytes.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PPARGC1A" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=PPARGC1A</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>RICTOR</italic></td>
<td align="left"><bold>Rapamycin-insensitive companion of mammalian target of rapamycin</bold> (<bold>RICTOR</bold>) is a subunit of mTOR and part of the IRSP.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=rictor" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=rictor</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>RPS6KB1</italic></td>
<td align="left"><bold>Ribosomal protein S6 kinase beta-1 (S6K1)</bold>, aka <bold>p70S6 kinase</bold> (<bold>p70S6K</bold>, <bold>p70-S6K</bold>), is a protein kinase that phosphorylates threonine 389 and activates mTOR and correlated with autophagy inhibition. The kinase activity of RPS6KB1 protein leads to an increase in protein synthesis and cell proliferation. It is expressed in most cell types.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=RPS6KB1" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=RPS6KB1</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>RPTOR</italic></td>
<td align="left"><bold>Regulatory-associated protein of mTOR</bold> AKA <bold>KIAA1303</bold> encodes part of a signaling pathway regulating cell growth responding to nutrient and insulin levels.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=RPTOR" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=RPTOR</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>SLC2A4</italic></td>
<td align="left"><bold>Glucose transporter type 4</bold>, aka <bold>GLUT4</bold> is the insulin-regulated glucose transporter found primarily in adipose tissues and striated muscle (skeletal and cardiac). It is expressed in most cell types, but especially in astrocytes.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=SLC2A4" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=SLC2A4</ext-link></td>
<td align="center">IRSP related</td>
</tr>
<tr>
<td align="left"><italic>TBC1D4</italic></td>
<td align="left"><bold>TBC1 domain family member 4</bold> now known as <bold>AS160</bold> encodes Rba GTPase-activating protein and is a substrate for Akt2.<break/><ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=TBC1D4" xlink:type="simple">http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=TBC1D4</ext-link></td>
<td align="center">IRSP related</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<sec id="sec010">
<title>Altered mRNA expression in whole tissue homogenates of the parahippocampal gyrus in AD and anti-T2D medicated AD</title>
<p>Compared to controls, 12 of the 18-endothelial cell and IRSP-associated genes assayed were significantly (12 of 18 unadjusted ps&lt;0.05; 6 of 12 after FDR correction) altered in AD (Figs <xref ref-type="fig" rid="pone.0206547.g002">2</xref> and <xref ref-type="fig" rid="pone.0206547.g003">3</xref>). One third of the altered genes (unadjusted ps&lt;0.05), or 44% after FDR correction, were genes with preponderant expression in endothelial cells[<xref ref-type="bibr" rid="pone.0206547.ref074">74</xref>]. In AD donors who had a history of receiving antidiabetic treatment, only 4 of these 12 genes remained significant before FDR correction and only 1 (<italic>ANGPT1</italic>) after FDR correction.</p>
<fig id="pone.0206547.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Endothelial cell markers in parahippocampal gyrus bulk tissue.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDR correction; # = p&lt;0.05 without FDR correction; ✦ = p&lt;0.05 AD-No Treatment vs. AD-T2D Treatment.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0206547.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.g003</object-id>
<label>Fig 3</label>
<caption>
<title>IRSP-associated markers in parahippocampal gyrus bulk tissue.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDR correction; # = p&lt;0.05 without FDR correction; ✦ = p&lt;0.05 AD-No Treatment vs. AD-T2D Treatment.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec011">
<title>Altered mRNA expression in endothelial cells of the parahippocampal gyrus in AD and anti-T2D medicated AD</title>
<p>Compared to EC enriched fraction of controls, 5 (unadjusted for FDR) endothelial and IRSP-related genes were abnormally expressed in untreated persons with AD (Figs <xref ref-type="fig" rid="pone.0206547.g004">4</xref> and <xref ref-type="fig" rid="pone.0206547.g005">5</xref>). None of the IRSP/endothelial cell associated genes, except for AKT3, met the FDR corrected threshold. Only one of these 5 genes (<italic>IRS1</italic>) remained significantly different in expression in the endothelial cell fraction of treated persons with AD, and even the expression levels of this gene approached that of the controls, nominally. Interestingly, the expression level of IRS1 was not changed in the endothelial fractions derived from persons with AD, but its expression increased significantly (corrected p = 0.05) in those AD donors who had been treated with antidiabetic medications.</p>
<fig id="pone.0206547.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Endothelial cell markers in microvascular enriched isolates from the parahippocampal gyrus.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDR correction; # = p&lt;0.05 without FDR correction; ✦ = p&lt;0.05 AD-No Treatment vs. AD-T2D Treatment.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.g004" xlink:type="simple"/>
</fig>
<fig id="pone.0206547.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0206547.g005</object-id>
<label>Fig 5</label>
<caption>
<title>IRSP-associated markers in microvascular enriched isolates from the parahippocampal gyrus.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDR correction; # = p&lt;0.05 without FDR correction; ✦ = p&lt;0.05 AD-No Treatment vs. AD-T2D Treatment.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec012">
<title>Non-IRSP and/or non-endothelial cell mRNAs in the parahippocampal gyrus in AD and anti-T2D medicated AD</title>
<p>Twenty-three mRNAs representing neuronal, oligodendroglial, astrocytic, microglial cell types, and cell-cell adhesion, inflammation/immune, cell fate markers were also selected (<xref ref-type="supplementary-material" rid="pone.0206547.s001">S1 File</xref>) to study the consequences of antidiabetic treatment on some of the more non-IRSP/endothelial cell functions of the parahippocampal gyrus. Not surprisingly, the expression of 8 of the 23 mRNAs studied was affected in the whole tissue homogenates of untreated persons with AD and included mRNAs encoding for proteins associated with synaptic function, astrocytes, cell adhesion and immune/inflammation responses. Treatment with antidiabetic medications reduced the number of adversely affected mRNAs to 3 that included markers of immune/inflammation and cell-cell adhesion. Significantly fewer of these markers were affected in the endothelial cell enriched fraction, where 2 (oligodendroglial and nuclear RNA retention) of the 23 markers were affected in untreated AD samples and altered expression remained significant, albeit nominally moderated in the treatment group.</p>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>Numerous clinical, animal model, and postmortem studies have suggested that treatment of persons suffering from dementia with antidiabetic medications may have beneficial effects on cognitive function and on AD-related neuropathology[<xref ref-type="bibr" rid="pone.0206547.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0206547.ref026">26</xref>]. A number of recent studies and reviews have drawn attention to the role(s) of the brain microvasculature in dementia[<xref ref-type="bibr" rid="pone.0206547.ref056">56</xref>] and especially in persons with diabetes[<xref ref-type="bibr" rid="pone.0206547.ref055">55</xref>, <xref ref-type="bibr" rid="pone.0206547.ref056">56</xref>, <xref ref-type="bibr" rid="pone.0206547.ref081">81</xref>]. The current study was designed to uncover some of the transcriptomic substrates for microvascular abnormalities in AD and to delineate whether any beneficial effects of T2D medications could be attributed to the restoration of microvascular and endothelial cell attributes affected in AD.</p>
<p>The results indicated that there are considerable abnormalities and reductions in gene expression (whole tissue homogenates and endothelial cell isolates) in the parahippocampal gyrus of persons with AD that map directly to genes associated with the microvasculature and the IRSP. Whether these endothelial and IRSP abnormalities contribute to the genesis of AD neuropathology, or whether they result from other neuropathological changes cannot be determined in postmortem studies. The findings also showed that the numbers of abnormally expressed microvasculature and IRSP associated genes in diabetic AD donors who had been treated with anti-diabetic agents were reduced significantly. Of course, it can be argued that in the absence of untreated studied cases with AD and T2D, the “normalization” of microvasculature and the IRSP gene expression could be due to T2D and not its treatment. Although this argument cannot be countered by the results of this study, we find this alternative explanation to be less biologically plausible given knowledge of the well-documented detrimental effects of T2D on brain parenchyma and especially on the brain microvasculature. The interpretation that treatment of T2D “normalized” multiple transcriptional abnormalities associated with AD is, however, consistent with the results of some of the clinical trials reported to date[<xref ref-type="bibr" rid="pone.0206547.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0206547.ref082">82</xref>] as well as our earlier studies of the effects of anti-diabetic treatments on AD neuropathology[<xref ref-type="bibr" rid="pone.0206547.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0206547.ref027">27</xref>]. That AKT3 expression was dramatically and robustly reduced in endothelial cells, and to a lesser extent in whole tissue homogenates suggests that tissue level expression was driven by changes in the endothelial transcriptome and that the disruption of components of the IRSP in endothelial cells is a significant participant in AD neuropathology.</p>
<p>The expression levels of <italic>GLUT4</italic> (<italic>SLC2A4</italic>), which encodes for an insulin-regulated glucose transporter, were significantly upregulated in bulk tissue from the parahippocampal gyrus of AD donors (<xref ref-type="fig" rid="pone.0206547.g003">Fig 3</xref>), while the expression levels of this same transcript were significantly reduced in the endothelial cell enriched isolates derived from the same donors and brain region. On the other hand, the expression levels of <italic>GLUT4</italic> in persons with AD and T2D who had been treated with anti-diabetic medications were similar to the levels detected in controls. This suggests that anti-diabetic medications restored homeostasis to this critical glucose transporter and that dis-homeostasis of glucose transport in brain endothelial and non-endothelial cells may be a critical abnormality in AD that is restored by anti-diabetes medications. Animal model and <italic>in vitro</italic> studies will need to be conducted to determine whether dysregulation of <italic>GLUT4</italic> may be a key contributor to at least some of the other IRSP and endothelial cell abnormalities observed in the current study. Zlokovic and colleagues have independently implicated GLUT1, another glucose transporter, as a key player in the microvascular pathology associated with AD[<xref ref-type="bibr" rid="pone.0206547.ref083">83</xref>].</p>
<p>“Normalization” of abnormally expressed genes in AD by anti-T2D treatment was not limited to transcripts associated with the IRSP and endothelial cells, but as shown in Figs <xref ref-type="fig" rid="pone.0206547.g001">1</xref> and <xref ref-type="fig" rid="pone.0206547.g002">2</xref> of the <xref ref-type="supplementary-material" rid="pone.0206547.s001">S1 File</xref> carried over to genes associated with immune-inflammation, microglia, cell-adhesion and synaptic function. These findings are not surprising if it is assumed that treatment with anti-T2D medications results in decreased overall inflammation and improved insulin signaling.</p>
<p>The fact that no brains from AD+T2D diabetic donors that had not been treated with antidiabetic agents were included in this study is a distinct weakness and detracts from interpretative power. However, in developed countries, the vast majority of persons diagnosed with T2D receive insulin or oral anti-diabetes medications, making it difficult to include such a group in clinical and postmortem studies. In addition, interpretation of results, even if such a group had been included, would have been hampered since, almost by definition, the severity of T2D would have been significantly less than that of the treated subjects. Despite the imperfect nature of mouse models, these variables will be easier to control in such a system, and we plan to attempt to address some of these questions left open in our postmortem human studies by employing mouse models of amyloidosis or tauopathy, each of which will be studied without or with diabetes, and each of those groups, in turn, can be studied with or without antidiabetic medication. Choice of the adequate mouse model of diabetes will be key since we have observed some unexpected effects in some transgenic mouse models for amyloidosis[<xref ref-type="bibr" rid="pone.0206547.ref084">84</xref>] and the effect of a deficiency of the T2D gene, <italic>Sorcs1</italic>[<xref ref-type="bibr" rid="pone.0206547.ref085">85</xref>]. Finally, we might also need to examine the effects of young ages vs older as additional parameters in this highly ambitious study.</p>
<p>As noted in <xref ref-type="table" rid="pone.0206547.t001">Table 1</xref>, the great majority of the donors (79+%) who were treated with oral anti-diabetes agents were treated with sulfonylureas. Although this makes it easier to attribute any oral medication effects to sulfonylureas, it detracts from our ability to distinguish between the effects of the myriad of different agents with different mechanisms of action. The inability to discern the specific neuro/vascular effects of different anti-diabetic agents in this study also precluded our ability to assess how the reported interactions of metformin and APP/Aβ influence IRSP and endothelial cell markers[<xref ref-type="bibr" rid="pone.0206547.ref086">86</xref>–<xref ref-type="bibr" rid="pone.0206547.ref088">88</xref>]. In addition, it would have been of significant interest to stratify the studied cohort according to whether they received insulin only, oral agents only, or insulin plus oral agents as well as the efficacy and duration of treatment. Unfortunately, extended medical histories (e.g., since mid-life) were not available since the study cohort was nursing home based and the sample size was not large enough for adequate statistical power to analyze the results with medication type granularity.</p>
<p>Challenge notwithstanding, about half of diabetics develop dementia and that roughly doubles the cost of caring for each demented diabetic patient especially since their cognitive decline makes it impossible for the patient to participate in the monitoring and modulation of his/her diabetic status. Given the dual epidemics of T2D and dementia in the most rapidly growing segment of our population, there is enormous importance in elucidating the basis for cognitive impairment in T2D so that potentially meaningful interventions can be evaluated.</p>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0206547.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.s001" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>Other transcripts.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0206547.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.s002" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>Original raw data.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0206547.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.s003" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Significantly affected non-endothelial and non-IRSP associated transcripts in parahippocampal gyrus bulk tissue.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDC correction; # = p&lt;0.05 without FDR correction.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0206547.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0206547.s004" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Significantly affected non-endothelial and non-IRSP associated transcripts in microvascular enriched isolates from the parahippocampal gyrus.</title>
<p>Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p&lt;0.05 after FDC correction; # = p&lt;0.05 without FDR correction.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0206547.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ravona-Springer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Moshier</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Godbold</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Akrivos</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rapp</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Changes in glycemic control are associated with changes in cognition in non-diabetic elderly</article-title>. <source>J Alzheimers Dis</source>. <year>2012</year>;<volume>30</volume>(<issue>2</issue>):<fpage>299</fpage>–<lpage>309</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-2012-120106" xlink:type="simple">10.3233/JAD-2012-120106</ext-link></comment> <object-id pub-id-type="pmid">22426020</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ravona-Springer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Luo</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wysocki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lesser</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Rapp</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Diabetes is associated with increased rate of cognitive decline in questionably demented elderly</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2010</year>;<volume>29</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000265552" xlink:type="simple">10.1159/000265552</ext-link></comment> <object-id pub-id-type="pmid">20130405</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Janson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Laedtke</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Parisi</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>O’Brien</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Petersen</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Butler</surname> <given-names>PC</given-names></name>. <article-title>Increased risk of type 2 diabetes in Alzheimer disease</article-title>. <source>Diabetes</source>. <year>2004</year>;<volume>53</volume>(<issue>2</issue>):<fpage>474</fpage>–<lpage>81</lpage>. <object-id pub-id-type="pmid">14747300</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salameh</surname> <given-names>TS</given-names></name>, <name name-style="western"><surname>Bullock</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Hujoel</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Niehoff</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Wolden-Hanson</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition</article-title>. <source>J Alzheimers Dis</source>. <year>2015</year>;<volume>47</volume>(<issue>3</issue>):<fpage>715</fpage>–<lpage>28</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-150307" xlink:type="simple">10.3233/JAD-150307</ext-link></comment> <object-id pub-id-type="pmid">26401706</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Winblad</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Fratiglioni</surname> <given-names>L</given-names></name>. <article-title>The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease</article-title>. <source>Diabetes</source>. <year>2007</year>;<volume>56</volume>(<issue>1</issue>):<fpage>211</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db06-0879" xlink:type="simple">10.2337/db06-0879</ext-link></comment> <object-id pub-id-type="pmid">17192484</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Caracciolo</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HX</given-names></name>, <name name-style="western"><surname>Winblad</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Backman</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Accelerated progression from mild cognitive impairment to dementia in people with diabetes</article-title>. <source>Diabetes</source>. <year>2010</year>;<volume>59</volume>(<issue>11</issue>):<fpage>2928</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db10-0539" xlink:type="simple">10.2337/db10-0539</ext-link></comment> <object-id pub-id-type="pmid">20713684</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neth</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>. <article-title>Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages</article-title>. <source>Frontiers in aging neuroscience</source>. <year>2017</year>;<volume>9</volume>:<fpage>345</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnagi.2017.00345" xlink:type="simple">10.3389/fnagi.2017.00345</ext-link></comment> <object-id pub-id-type="pmid">29163128</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Bussel</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Backes</surname> <given-names>WH</given-names></name>, <name name-style="western"><surname>Hofman</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>van Oostenbrugge</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Kessels</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>van Boxtel</surname> <given-names>MP</given-names></name>, <etal>et al</etal>. <article-title>On the interplay of microvasculature, parenchyma, and memory in type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>(<issue>5</issue>):<fpage>876</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/dc14-2043" xlink:type="simple">10.2337/dc14-2043</ext-link></comment> <object-id pub-id-type="pmid">25690006</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kerti</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Witte</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Winkler</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Grittner</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Rujescu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Floel</surname> <given-names>A</given-names></name>. <article-title>Higher glucose levels associated with lower memory and reduced hippocampal microstructure</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>81</volume>(<issue>20</issue>):<fpage>1746</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1212/01.wnl.0000435561.00234.ee" xlink:type="simple">10.1212/01.wnl.0000435561.00234.ee</ext-link></comment> <object-id pub-id-type="pmid">24153444</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hayashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kurioka</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Morita</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kanazawa</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Takase</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Association of cognitive dysfunction with hippocampal atrophy in elderly Japanese people with type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2011</year>;<volume>94</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.diabres.2011.07.002" xlink:type="simple">10.1016/j.diabres.2011.07.002</ext-link></comment> <object-id pub-id-type="pmid">21835484</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname> <given-names>WQ</given-names></name>, <name name-style="western"><surname>De Felice</surname> <given-names>FG</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lambert</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Quon</surname> <given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Amyloid beta oligomers induce impairment of neuronal insulin receptors</article-title>. <source>FASEB J</source>. <year>2008</year>;<volume>22</volume>(<issue>1</issue>):<fpage>246</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1096/fj.06-7703com" xlink:type="simple">10.1096/fj.06-7703com</ext-link></comment> <object-id pub-id-type="pmid">17720802</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Felice</surname> <given-names>FG</given-names></name>, <name name-style="western"><surname>Ferreira</surname> <given-names>ST</given-names></name>. <article-title>Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>7</issue>):<fpage>2262</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db13-1954" xlink:type="simple">10.2337/db13-1954</ext-link></comment> <object-id pub-id-type="pmid">24931033</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ruiz</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Chi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Lindtner</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hsieh</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Ehrlich</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer’s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>8</issue>):<fpage>851</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jalz.2016.01.008" xlink:type="simple">10.1016/j.jalz.2016.01.008</ext-link></comment> <object-id pub-id-type="pmid">26928090</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Asthana</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cook</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Cherrier</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Purganan</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype</article-title>. <source>Psychoneuroendocrinology</source>. <year>2003</year>;<volume>28</volume>(<issue>6</issue>):<fpage>809</fpage>–<lpage>22</lpage>. <object-id pub-id-type="pmid">12812866</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Risner</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Saunders</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Ormandy</surname> <given-names>GC</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Foley</surname> <given-names>IM</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease</article-title>. <source>PharmacogenomicsJ</source>. <year>2006</year>;<volume>6</volume>(<issue>4</issue>):<fpage>246</fpage>–<lpage>54</lpage>.</mixed-citation></ref>
<ref id="pone.0206547.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ryan</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Freed</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Rood</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Cobitz</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Waterhouse</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Strachan</surname> <given-names>MW</given-names></name>. <article-title>Improving metabolic control leads to better working memory in adults with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>2</issue>):<fpage>345</fpage>–<lpage>51</lpage>. <object-id pub-id-type="pmid">16443885</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Imfeld</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bodmer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jick</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Meier</surname> <given-names>CR</given-names></name>. <article-title>Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study</article-title>. <source>J Am Geriatr Soc</source>. <year>2012</year>;<volume>60</volume>(<issue>5</issue>):<fpage>916</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1532-5415.2012.03916.x" xlink:type="simple">10.1111/j.1532-5415.2012.03916.x</ext-link></comment> <object-id pub-id-type="pmid">22458300</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saxena</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Elbers</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Peter</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Gaunt</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Mega</surname> <given-names>JL</given-names></name>, <etal>et al</etal>. <article-title>Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci</article-title>. <source>Am J Hum Genet</source>. <year>2012</year>;<volume>90</volume>(<issue>3</issue>):<fpage>410</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2011.12.022" xlink:type="simple">10.1016/j.ajhg.2011.12.022</ext-link></comment> <object-id pub-id-type="pmid">22325160</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arnold</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Arvanitakis</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Macauley-Rambach</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Koenig</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Ahima</surname> <given-names>RS</given-names></name>, <etal>et al</etal>. <article-title>Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums</article-title>. <source>Nature reviews Neurology</source>. <year>2018</year>;<volume>14</volume>(<issue>3</issue>):<fpage>168</fpage>–<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneurol.2017.185" xlink:type="simple">10.1038/nrneurol.2017.185</ext-link></comment> <object-id pub-id-type="pmid">29377010</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Moore</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Meiri</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Quon</surname> <given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats</article-title>. <source>JBiolChem</source>. <year>1999</year>;<volume>274</volume>(<issue>49</issue>):<fpage>34893</fpage>–<lpage>902</lpage>.</mixed-citation></ref>
<ref id="pone.0206547.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zimmerman</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Hobbs</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Wells</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>SX</given-names></name>, <name name-style="western"><surname>Kattan</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Bouchard</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1555</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12969" xlink:type="simple">10.1111/dom.12969</ext-link></comment> <object-id pub-id-type="pmid">28407414</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gough</surname> <given-names>NR</given-names></name>. <article-title>Placing the nuclear pore in the metformin mechanism of action</article-title>. <source>Sci Signal</source>. <year>2017</year>;<volume>10</volume>(<issue>460</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scisignal.aam6836" xlink:type="simple">10.1126/scisignal.aam6836</ext-link></comment> <object-id pub-id-type="pmid">28049772</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanahuja</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Alonso</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Diez</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ortega</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Rubinat</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Traveset</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Increased Burden of Cerebral Small Vessel Disease in Patients With Type 2 Diabetes and Retinopathy</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>(<issue>9</issue>):<fpage>1614</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/dc15-2671" xlink:type="simple">10.2337/dc15-2671</ext-link></comment> <object-id pub-id-type="pmid">27281772</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Claxton</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Hanson</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Cholerton</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Trittschuh</surname> <given-names>EH</given-names></name>, <etal>et al</etal>. <article-title>Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>57</volume>(<issue>4</issue>):<fpage>1325</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-161256" xlink:type="simple">10.3233/JAD-161256</ext-link></comment> <object-id pub-id-type="pmid">28372335</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Watson</surname> <given-names>GS</given-names></name>. <article-title>Insulin and neurodegenerative disease: shared and specific mechanisms</article-title>. <source>Lancet Neurol</source>. <year>2004</year>;<volume>3</volume>(<issue>3</issue>):<fpage>169</fpage>–<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(04)00681-7" xlink:type="simple">10.1016/S1474-4422(04)00681-7</ext-link></comment> <object-id pub-id-type="pmid">14980532</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beeri</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Silverman</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Gandy</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wysocki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hannigan</surname> <given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>71</volume>(<issue>10</issue>):<fpage>750</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1212/01.wnl.0000324925.95210.6d" xlink:type="simple">10.1212/01.wnl.0000324925.95210.6d</ext-link></comment> <object-id pub-id-type="pmid">18765651</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beeri</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Silverman</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Marin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Grossman</surname> <given-names>HZ</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Type 2 diabetes is negatively associated with Alzheimer’s disease neuropathology</article-title>. <source>Journals of Gerontology Series A-Biological Sciences and Medical Sciences</source>. <year>2005</year>;<volume>60</volume>(<issue>4</issue>):<fpage>471</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pone.0206547.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Willette</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Birdsill</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Sager</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Christian</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>LD</given-names></name>, <etal>et al</etal>. <article-title>Insulin resistance predicts brain amyloid deposition in late middle-aged adults</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>5</issue>):<fpage>504</fpage>–<lpage>10 e1</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jalz.2014.03.011" xlink:type="simple">10.1016/j.jalz.2014.03.011</ext-link></comment> <object-id pub-id-type="pmid">25043908</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Shaikenov</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Peterson</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Aimbetov</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bissenbaev</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>SW</given-names></name>, <etal>et al</etal>. <article-title>ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor</article-title>. <source>SciSignal</source>. <year>2011</year>;<volume>4</volume>(<issue>161</issue>):<fpage>ra10</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scisignal.2001731" xlink:type="simple">10.1126/scisignal.2001731</ext-link></comment> <object-id pub-id-type="pmid">21343617</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anderton</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Dayanandan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Killick</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lovestone</surname> <given-names>S</given-names></name>. <article-title>Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer’s disease?</article-title> <source>MolMedToday</source>. <year>2000</year>;<volume>6</volume>(<issue>2</issue>):<fpage>54</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="pone.0206547.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de la Monte</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Wands</surname> <given-names>JR</given-names></name>. <article-title>Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease</article-title>. <source>J Alzheimers Dis</source>. <year>2005</year>;<volume>7</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>61</lpage>. <object-id pub-id-type="pmid">15750214</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Foster</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Landfield</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Maier</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>Resnick</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Yaffe</surname> <given-names>K</given-names></name>. <article-title>Session III: Mechanisms of Age-Related Cognitive Change and Targets for Intervention: Inflammatory, Oxidative, and Metabolic Processes</article-title>. <source>JGerontolA BiolSciMedSci</source>. <year>2012</year>;<volume>67</volume>(<issue>7</issue>):<fpage>754</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/gerona/gls112" xlink:type="simple">10.1093/gerona/gls112</ext-link></comment> <object-id pub-id-type="pmid">22570133</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Hsu</surname> <given-names>KS</given-names></name>. <article-title>Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways</article-title>. <source>Neuropharmacology</source>. <year>2011</year>;<volume>61</volume>(<issue>4</issue>):<fpage>867</fpage>–<lpage>79</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neuropharm.2011.06.003" xlink:type="simple">10.1016/j.neuropharm.2011.06.003</ext-link></comment> <object-id pub-id-type="pmid">21683721</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arnold</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Lucki</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Brookshire</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Carlson</surname> <given-names>GC</given-names></name>, <name name-style="western"><surname>Browne</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Kazi</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice</article-title>. <source>Neurobiol Dis</source>. <year>2014</year>;<volume>67</volume>:<fpage>79</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbd.2014.03.011" xlink:type="simple">10.1016/j.nbd.2014.03.011</ext-link></comment> <object-id pub-id-type="pmid">24686304</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jiang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Heneka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Landreth</surname> <given-names>GE</given-names></name>. <article-title>The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications</article-title>. <source>CNS Drugs</source>. <year>2008</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00023210-200822010-00001" xlink:type="simple">10.2165/00023210-200822010-00001</ext-link></comment> <object-id pub-id-type="pmid">18072811</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salvado</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Serrano-Marco</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Barroso</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Palomer</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Vazquez-Carrera</surname> <given-names>M</given-names></name>. <article-title>Targeting PPARbeta/delta for the treatment of type 2 diabetes mellitus</article-title>. <source>ExpertOpinTherTargets</source>. <year>2012</year>;<volume>16</volume>(<issue>2</issue>):<fpage>209</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1517/14728222.2012.658370" xlink:type="simple">10.1517/14728222.2012.658370</ext-link></comment> <object-id pub-id-type="pmid">22280315</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akram</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Hof</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>. <article-title>Increased expression of RXRalpha in dementia: an early harbinger for the cholesterol dyshomeostasis?</article-title> <source>Mol Neurodegener</source>. <year>2010</year>;<volume>5</volume>:<fpage>36</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1750-1326-5-36" xlink:type="simple">10.1186/1750-1326-5-36</ext-link></comment> <object-id pub-id-type="pmid">20843353</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qin</surname> <given-names>WP</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Cardozo</surname> <given-names>CP</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Buxbaum</surname> <given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>PGC-1 alpha Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia</article-title>. <source>Archives of Neurology</source>. <year>2009</year>;<volume>66</volume>(<issue>3</issue>):<fpage>352</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/archneurol.2008.588" xlink:type="simple">10.1001/archneurol.2008.588</ext-link></comment> <object-id pub-id-type="pmid">19273754</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van der Heide</surname> <given-names>LP</given-names></name>, <name name-style="western"><surname>Ramakers</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Smidt</surname> <given-names>MP</given-names></name>. <article-title>Insulin signaling in the central nervous system: learning to survive</article-title>. <source>ProgNeurobiol</source>. <year>2006</year>;<volume>79</volume>(<issue>4</issue>):<fpage>205</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pneurobio.2006.06.003" xlink:type="simple">10.1016/j.pneurobio.2006.06.003</ext-link></comment> <object-id pub-id-type="pmid">16916571</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gray</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Meijer</surname> <given-names>RI</given-names></name>, <name name-style="western"><surname>Barrett</surname> <given-names>EJ</given-names></name>. <article-title>Insulin regulates brain function, but how does it get there?</article-title> <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>12</issue>):<fpage>3992</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db14-0340" xlink:type="simple">10.2337/db14-0340</ext-link></comment> <object-id pub-id-type="pmid">25414013</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arvanitakis</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Arnold</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Diabetes is related to cerebral infarction but not to AD pathology in older persons</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>(<issue>11</issue>):<fpage>1960</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1212/01.wnl.0000247053.45483.4e" xlink:type="simple">10.1212/01.wnl.0000247053.45483.4e</ext-link></comment> <object-id pub-id-type="pmid">17159101</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stoeckel</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Arvanitakis</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Gandy</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Small</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kahn</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pascual-Leone</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>"White Paper" meeting summary and catalyst for future inquiry: Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction</article-title>. <source>F1000Research</source>. <year>2016</year>;<volume>5</volume>(<issue>353</issue>).</mixed-citation></ref>
<ref id="pone.0206547.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hsu</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Kanoski</surname> <given-names>SE</given-names></name>. <article-title>Blood-brain barrier disruption: mechanistic links between Western diet consumption and dementia</article-title>. <source>Frontiers in aging neuroscience</source>. <year>2014</year>;<volume>6</volume>:<fpage>88</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnagi.2014.00088" xlink:type="simple">10.3389/fnagi.2014.00088</ext-link></comment> <object-id pub-id-type="pmid">24847262</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xie</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Helmerhorst</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Taddei</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Plewright</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Van Bronswijk</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Martins</surname> <given-names>R</given-names></name>. <article-title>Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor</article-title>. <source>J Neurosci</source>. <year>2002</year>;<volume>22</volume>(<issue>10</issue>):<fpage>RC221</fpage>. <object-id pub-id-type="pmid">12006603</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Felice</surname> <given-names>FG</given-names></name>, <name name-style="western"><surname>Vieira</surname> <given-names>MN</given-names></name>, <name name-style="western"><surname>Bomfim</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Decker</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Velasco</surname> <given-names>PT</given-names></name>, <name name-style="western"><surname>Lambert</surname> <given-names>MP</given-names></name>, <etal>et al</etal>. <article-title>Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers</article-title>. <source>ProcNatlAcad Sci US A</source>. <year>2009</year>;<volume>106</volume>(<issue>6</issue>):<fpage>1971</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="pone.0206547.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>. <article-title>Alzheimer disease: Insulin resistance and AD—extending the translational path</article-title>. <source>Nature reviews Neurology</source>. <year>2012</year>;<volume>8</volume>(<issue>7</issue>):<fpage>360</fpage>–<lpage>2</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneurol.2012.112" xlink:type="simple">10.1038/nrneurol.2012.112</ext-link></comment> <object-id pub-id-type="pmid">22710630</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yemul</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Knable</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer’s disease cases</article-title>. <source>IntJAlzheimersDis</source>. <year>2012</year>;<volume>2012</volume>:<fpage>321280</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2012/321280" xlink:type="simple">10.1155/2012/321280</ext-link></comment> <object-id pub-id-type="pmid">22666619</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Talbot</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Kazi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Bakshi</surname> <given-names>KP</given-names></name>, <name name-style="western"><surname>Stucky</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline</article-title>. <source>JClinInvest</source>. <year>2012</year>;<volume>122</volume>(<issue>4</issue>):<fpage>1316</fpage>–<lpage>38</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI59903" xlink:type="simple">10.1172/JCI59903</ext-link></comment> <object-id pub-id-type="pmid">22476197</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Starr</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Farrall</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Armitage</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>McGurn</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Wardlaw</surname> <given-names>J</given-names></name>. <article-title>Blood-brain barrier permeability in Alzheimer’s disease: a case-control MRI study</article-title>. <source>Psychiatry Res</source>. <year>2009</year>;<volume>171</volume>(<issue>3</issue>):<fpage>232</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pscychresns.2008.04.003" xlink:type="simple">10.1016/j.pscychresns.2008.04.003</ext-link></comment> <object-id pub-id-type="pmid">19211227</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bell</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Zlokovic</surname> <given-names>BV</given-names></name>. <article-title>Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease</article-title>. <source>Acta Neuropathol</source>. <year>2009</year>;<volume>118</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00401-009-0522-3" xlink:type="simple">10.1007/s00401-009-0522-3</ext-link></comment> <object-id pub-id-type="pmid">19319544</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bell</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Sagare</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Friedman</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Bedi</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Holtzman</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Deane</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system</article-title>. <source>JCerebBlood Flow Metab</source>. <year>2007</year>;<volume>27</volume>(<issue>5</issue>):<fpage>909</fpage>–<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.jcbfm.9600419" xlink:type="simple">10.1038/sj.jcbfm.9600419</ext-link></comment> <object-id pub-id-type="pmid">17077814</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zlokovic</surname> <given-names>BV</given-names></name>. <article-title>Neurovascular mechanisms of Alzheimer’s neurodegeneration</article-title>. <source>Trends Neurosci</source>. <year>2005</year>;<volume>28</volume>(<issue>4</issue>):<fpage>202</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tins.2005.02.001" xlink:type="simple">10.1016/j.tins.2005.02.001</ext-link></comment> <object-id pub-id-type="pmid">15808355</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Silva</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Faraci</surname> <given-names>FM</given-names></name>. <article-title>Microvascular Dysfunction and Cognitive Impairment</article-title>. <source>Cell Mol Neurobiol</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>241</fpage>–<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10571-015-0308-1" xlink:type="simple">10.1007/s10571-015-0308-1</ext-link></comment> <object-id pub-id-type="pmid">26988697</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wardlaw</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dichgans</surname> <given-names>M</given-names></name>. <article-title>Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging</article-title>. <source>Lancet Neurol</source>. <year>2013</year>;<volume>12</volume>(<issue>5</issue>):<fpage>483</fpage>–<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(13)70060-7" xlink:type="simple">10.1016/S1474-4422(13)70060-7</ext-link></comment> <object-id pub-id-type="pmid">23602162</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barrett</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Khamaisi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>GL</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>BEK</given-names></name>, <etal>et al</etal>. <article-title>Diabetic Microvascular Disease: An Endocrine Society Scientific Statement</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2017</year>;<volume>102</volume>(<issue>12</issue>):<fpage>4343</fpage>–<lpage>410</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2017-01922" xlink:type="simple">10.1210/jc.2017-01922</ext-link></comment> <object-id pub-id-type="pmid">29126250</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snyder</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Corriveau</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Faber</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Greenberg</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Knopman</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>6</issue>):<fpage>710</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jalz.2014.10.008" xlink:type="simple">10.1016/j.jalz.2014.10.008</ext-link></comment> <object-id pub-id-type="pmid">25510382</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thomas</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Miners</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Love</surname> <given-names>S</given-names></name>. <article-title>Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer’s disease and vascular dementia</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>Pt 4</issue>):<fpage>1059</fpage>–<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/brain/awv025" xlink:type="simple">10.1093/brain/awv025</ext-link></comment> <object-id pub-id-type="pmid">25688080</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gorelick</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Scuteri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Black</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Decarli</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Greenberg</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Iadecola</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>9</issue>):<fpage>2672</fpage>–<lpage>713</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STR.0b013e3182299496" xlink:type="simple">10.1161/STR.0b013e3182299496</ext-link></comment> <object-id pub-id-type="pmid">21778438</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jellinger</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Attems</surname> <given-names>J</given-names></name>. <article-title>Prevalence of dementia disorders in the oldest-old: an autopsy study</article-title>. <source>Acta Neuropathol</source>. <year>2010</year>;<volume>119</volume>(<issue>4</issue>):<fpage>421</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00401-010-0654-5" xlink:type="simple">10.1007/s00401-010-0654-5</ext-link></comment> <object-id pub-id-type="pmid">20204386</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brayne</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Richardson</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Matthews</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Fleming</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hunter</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Xuereb</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Neuropathological Correlates of Dementia in Over-80-Year-Old Brain Donors from the Population-Based Cambridge City over-75s Cohort (CC75C) Study</article-title>. <source>JAlzheimers Dis</source>. <year>2009</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-2009-1182" xlink:type="simple">10.3233/JAD-2009-1182</ext-link></comment> <object-id pub-id-type="pmid">19661624</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giannakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kovari</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Herrmann</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Hof</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Bouras</surname> <given-names>C</given-names></name>. <article-title>Interhemispheric Distribution of Alzheimer Disease and Vascular Pathology in Brain Aging</article-title>. <source>Stroke</source>. <year>2009</year>;<volume>40</volume>:<fpage>983</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.108.530337" xlink:type="simple">10.1161/STROKEAHA.108.530337</ext-link></comment> <object-id pub-id-type="pmid">19118241</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giannakopoulos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gold</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Kovari</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Von Gunten</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Imhof</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bouras</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience</article-title>. <source>Acta Neuropathol</source>. <year>2007</year>;<volume>113</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00401-006-0144-y" xlink:type="simple">10.1007/s00401-006-0144-y</ext-link></comment> <object-id pub-id-type="pmid">17036244</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bouras</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kovari</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Herrmann</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Rivara</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Bailey</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Von Gunten</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status</article-title>. <source>Journal of Neuropathology and Experimental Neurology</source>. <year>2006</year>;<volume>65</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.jnen.0000203077.53080.2c" xlink:type="simple">10.1097/01.jnen.0000203077.53080.2c</ext-link></comment> <object-id pub-id-type="pmid">16651885</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bailey</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Rivara</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Perl</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bouras</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Giannakopoulos</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Hippocampal microvasculature attrition and cognitive decline in Alzheimers disease</article-title>. <source>Journal of Neuropathology and Experimental Neurology</source>; 5/20052005. p. <fpage>467</fpage>-.</mixed-citation></ref>
<ref id="pone.0206547.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Di Marco</surname> <given-names>LY</given-names></name>, <name name-style="western"><surname>Venneri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Farkas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Marzo</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Frangi</surname> <given-names>AF</given-names></name>. <article-title>Vascular dysfunction in the pathogenesis of Alzheimer’s disease—A review of endothelium-mediated mechanisms and ensuing vicious circles</article-title>. <source>Neurobiol Dis</source>. <year>2015</year>;<volume>82</volume>:<fpage>593</fpage>–<lpage>606</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbd.2015.08.014" xlink:type="simple">10.1016/j.nbd.2015.08.014</ext-link></comment> <object-id pub-id-type="pmid">26311408</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gama Sosa</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Gasperi</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Rocher</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Janssen</surname> <given-names>WG</given-names></name>, <name name-style="western"><surname>Flores</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer’s disease mutations</article-title>. <source>Am J Pathol</source>. <year>2010</year>;<volume>176</volume>(<issue>1</issue>):<fpage>353</fpage>–<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2353/ajpath.2010.090482" xlink:type="simple">10.2353/ajpath.2010.090482</ext-link></comment> <object-id pub-id-type="pmid">20008141</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nicolakakis</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hamel</surname> <given-names>E</given-names></name>. <article-title>Neurovascular function in Alzheimer’s disease patients and experimental models</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2011</year>;<volume>31</volume>(<issue>6</issue>):<fpage>1354</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jcbfm.2011.43" xlink:type="simple">10.1038/jcbfm.2011.43</ext-link></comment> <object-id pub-id-type="pmid">21468088</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stirban</surname> <given-names>A</given-names></name>. <article-title>Microvascular dysfunction in the context of diabetic neuropathy</article-title>. <source>Curr Diab Rep</source>. <year>2014</year>;<volume>14</volume>(<issue>11</issue>):<fpage>541</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11892-014-0541-x" xlink:type="simple">10.1007/s11892-014-0541-x</ext-link></comment> <object-id pub-id-type="pmid">25189434</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ostergaard</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Finnerup</surname> <given-names>NB</given-names></name>, <name name-style="western"><surname>Terkelsen</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Olesen</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Drasbek</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Knudsen</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>(<issue>4</issue>):<fpage>666</fpage>–<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00125-014-3461-z" xlink:type="simple">10.1007/s00125-014-3461-z</ext-link></comment> <object-id pub-id-type="pmid">25512003</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref070"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clegg</surname> <given-names>LE</given-names></name>, <name name-style="western"><surname>Mac Gabhann</surname> <given-names>F</given-names></name>. <article-title>Systems biology of the microvasculature</article-title>. <source>Integr Biol (Camb)</source>. <year>2015</year>;<volume>7</volume>(<issue>5</issue>):<fpage>498</fpage>–<lpage>512</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1039/c4ib00296b" xlink:type="simple">10.1039/c4ib00296b</ext-link></comment> <object-id pub-id-type="pmid">25839068</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref071"><label>71</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eelen</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>de Zeeuw</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Simons</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Carmeliet</surname> <given-names>P</given-names></name>. <article-title>Endothelial cell metabolism in normal and diseased vasculature</article-title>. <source>Circ Res</source>. <year>2015</year>;<volume>116</volume>(<issue>7</issue>):<fpage>1231</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCRESAHA.116.302855" xlink:type="simple">10.1161/CIRCRESAHA.116.302855</ext-link></comment> <object-id pub-id-type="pmid">25814684</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref072"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adamo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Raizada</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>LeRoith</surname> <given-names>D</given-names></name>. <article-title>Insulin and insulin-like growth factor receptors in the nervous system</article-title>. <source>Mol Neurobiol</source>. <year>1989</year>;<volume>3</volume>(<issue>1–2</issue>):<fpage>71</fpage>–<lpage>100</lpage>. <object-id pub-id-type="pmid">2553069</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref073"><label>73</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>. <article-title>Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals</article-title>. <source>PLoS One</source>. <year>2009</year>;<volume>4</volume>(<issue>10</issue>):<fpage>e7642</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0007642" xlink:type="simple">10.1371/journal.pone.0007642</ext-link></comment> <object-id pub-id-type="pmid">19865478</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref074"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sloan</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Scholze</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>O’Keeffe</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>An RNA-sequencing Transcriptome and splicing database of Glia, neurons, and vascular cells of the cerebral cortex</article-title>. <source>J Neurosci</source>. <year>2014</year>;<volume>34</volume>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1523/jneurosci.1860-14.2014" xlink:type="simple">10.1523/jneurosci.1860-14.2014</ext-link></comment> <object-id pub-id-type="pmid">25186741</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref075"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Schmeidler</surname> <given-names>J</given-names></name>. <article-title>Transcriptional vulnerability of brain regions in Alzheimer’s disease and dementia</article-title>. <source>Neurobiol Aging</source>. <year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>561</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurobiolaging.2007.07.021" xlink:type="simple">10.1016/j.neurobiolaging.2007.07.021</ext-link></comment> <object-id pub-id-type="pmid">17845826</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref076"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Roussos</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>McKenzie</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Kajiwara</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Brennand</surname> <given-names>KJ</given-names></name>, <etal>et al</etal>. <article-title>Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease</article-title>. <source>Genome Med</source>. <year>2016</year>;<volume>8</volume>(<issue>1</issue>):<fpage>104</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13073-016-0355-3" xlink:type="simple">10.1186/s13073-016-0355-3</ext-link></comment> <object-id pub-id-type="pmid">27799057</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref077"><label>77</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gama-Sosa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>De Gasperi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Garcia</surname> <given-names>GP</given-names></name>, <name name-style="western"><surname>Triperson</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Searcy</surname> <given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Step-gradient isolation of the adult mammalian brain microvasculature through a layer of Ficoll-Paque PLUS</article-title>. <source>Microvascular Research</source>. <year>2016</year>;In press.</mixed-citation></ref>
<ref id="pone.0206547.ref078"><label>78</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Purohit</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Perl</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Marin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lantz</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>1999</year>;<volume>56</volume>(<issue>6</issue>):<fpage>713</fpage>–<lpage>8</lpage>. Epub 1999/11/24. <object-id pub-id-type="pmid">10369312</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref079"><label>79</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Perl</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Purohit</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Marin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lantz</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>1998</year>;<volume>55</volume>(<issue>9</issue>):<fpage>1185</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/archneur.55.9.1185" xlink:type="simple">10.1001/archneur.55.9.1185</ext-link></comment> <object-id pub-id-type="pmid">9740112</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref080"><label>80</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mirra</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Heyman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McKeel</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sumi</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Crain</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Brownlee</surname> <given-names>LM</given-names></name>, <etal>et al</etal>. <article-title>The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease</article-title>. <source>Neurology</source>. <year>1991</year>;<volume>41</volume>(<issue>4</issue>):<fpage>479</fpage>–<lpage>86</lpage>. <object-id pub-id-type="pmid">2011243</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref081"><label>81</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hughes</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>. <article-title>The role of insulin in the vascular contributions to age-related dementia</article-title>. <source>Biochim Biophys Acta</source>. <year>2016</year>;<volume>1862</volume>(<issue>5</issue>):<fpage>983</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbadis.2015.11.013" xlink:type="simple">10.1016/j.bbadis.2015.11.013</ext-link></comment> <object-id pub-id-type="pmid">26657615</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref082"><label>82</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Montine</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Minoshima</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Watson</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Claxton</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial</article-title>. <source>ArchNeurol</source>. <year>2012</year>;<volume>69</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>38</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/archneurol.2011.233" xlink:type="simple">10.1001/archneurol.2011.233</ext-link></comment> <object-id pub-id-type="pmid">21911655</object-id></mixed-citation></ref>
<ref id="pone.0206547.ref083"><label>83</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Winkler</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Nishida</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sagare</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Rege</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Bell</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Perlmutter</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration</article-title>. <source>Nat Neurosci</source>. <year>2015</year>;<volume>18</volume>(<issue>4</issue>):<fpage>521</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nn.3966" xlink:type="simple">10.1038/nn.3966</ext-link></comment> <object-id pub-id-type="pmid">25730668</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref084"><label>84</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lubitz</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Haroutunian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Katsel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Leroith</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Landa</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Castel</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Non-viability of crossing the Alzheimer mouse model Tg2576 with the type 2 diabetes mouse model ob/ob</article-title>. <source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>(<issue>7</issue>):<fpage>e19</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurobiolaging.2014.01.138" xlink:type="simple">10.1016/j.neurobiolaging.2014.01.138</ext-link></comment></mixed-citation></ref>
<ref id="pone.0206547.ref085"><label>85</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knight</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Harte</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Hsieh</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Glabe</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer’s APP/PSEN1 mice by gene targeting of diabetes/Alzheimer’s-related Sorcs1</article-title>. <source>Acta Neuropathol Commun</source>. <year>2016</year>;<volume>4</volume>:<fpage>16</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40478-016-0282-y" xlink:type="simple">10.1186/s40478-016-0282-y</ext-link></comment> <object-id pub-id-type="pmid">26916443</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref086"><label>86</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Picone</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Vilasi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Librizzi</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Contardi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nuzzo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Caruana</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates</article-title>. <source>Aging (Albany NY)</source>. <year>2016</year>;<volume>8</volume>(<issue>8</issue>):<fpage>1718</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/aging.101004" xlink:type="simple">10.18632/aging.101004</ext-link></comment></mixed-citation></ref>
<ref id="pone.0206547.ref087"><label>87</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Picone</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Nuzzo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Caruana</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Messina</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Barera</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vasto</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-kappaB activation: Use of insulin to attenuate metformin’s effect</article-title>. <source>Biochim Biophys Acta</source>. <year>2015</year>;<volume>1853</volume>(<issue>5</issue>):<fpage>1046</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbamcr.2015.01.017" xlink:type="simple">10.1016/j.bbamcr.2015.01.017</ext-link></comment> <object-id pub-id-type="pmid">25667085</object-id>.</mixed-citation></ref>
<ref id="pone.0206547.ref088"><label>88</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kwak</surname> <given-names>YD</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>10</issue>):<fpage>3907</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0807991106" xlink:type="simple">10.1073/pnas.0807991106</ext-link></comment> <object-id pub-id-type="pmid">19237574</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>